Demonstration of Pharmacodynamic Equivalence of Enoxaparin Rovi (100-mg Subcutaneous Injection) to Clexane® (100-mg Subcutaneous Injection) in Healthy Volunteers
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Enoxaparin sodium (Primary)
- Indications Deep vein thrombosis; Myocardial infarction; Unstable angina pectoris
- Focus Pharmacokinetics
- Sponsors Rovi
Most Recent Events
- 08 Dec 2017 New trial record